ClinicalTrials.gg
Active, not recruitingNCT06191744EPCORE™FL-2Updated Aug 4, 2026

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

A Phase 3 interventional study of Epcoritamab and Prednisone in Follicular Lymphoma (FL), sponsored by Genmab. Active, not recruiting at 266 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Genmab · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,095
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing epcoritamab in Lymphoma, Follicular — 7 open to participants now, 12 under way, 2 of them phase 3. epcoritamab · Lymphoma, Follicular.

Enrollment
Largest of 13
1,095 · median 78
Started
2024
with 2 others
Phase 3
2 of 13
none open now
Primary completion
2037-11
later than 11 of 11 live
Registered
7th of 13
by date
Lead sponsor
4 of 13
Genmab

Among the 13 studies testing epcoritamab in Lymphoma, Follicular, this one has the largest enrollment, is one of 3 that started in 2024, is one of 2 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 7th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

7 of the 13 studies testing epcoritamab in Lymphoma, Follicular are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About epcoritamab

epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing epcoritamab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed.

Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants with previously untreated FL will be enrolled in approximately 250 sites across the world.

Participants will receive R2 (intravenous [IV] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab. Participants may also receive investigator's choice chemoimmunotherapy (CIT): IV infusion of obinutuzumab (G) and IV injections of cyclophosphamide, IV injections of doxorubicin, IV injections of vincristine, oral tablets of prednisone (CHOP) [G-CHOP]/ R-CHOP or G and IV infusion of bendamustine (Benda) [G-Benda]/R-Benda. The total treatment duration will be 120 weeks for all arms except A2, which is 24 weeks of treatment.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Follicular Lymphoma (FL)

Keywords

  • Follicular Lymphoma (FL)
  • Non-Hodgkin's lymphoma (NHL)
  • Lymphoma
  • Cancer
  • Epcoritamab
  • Rituximab
  • Lenalidomide
  • Chemoimmunotherapy (CIT)
  • Obinutuzumab
  • Cyclophosphamide
  • Doxorubicin Hydrochloride
  • Vincristine Sulfate
  • Prednisone
  • Bendamustine (Benda)
  • R-CHOP
  • G-CHOP
  • R-Benda
  • G-Benda
  • EPCORE™FL-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of follicular lymphoma (FL).
  • Have CD20+, confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours.
  • Are willing and able to comply with procedures required in the protocol.
  • Must have stage, III, IV or II with bulky disease >= 7cm).
  • Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.
  • Has one or more target lesions:

    • A positron emission tomography (PET)/computerized tomography (CT) scan demonstrating PET-positive lesion(s), and
    • >=1 measurable nodal lesion (long axis >1.5cm) or >=1 measurable extra-nodal lesion (long axis >1.0 cm) on CT scan or MRI
  • (ECOG) performance status 0-2.
  • Able to receive at least one of the standard of care chemoimmunotherapy (CIT) treatment regimens: [Arm B] at the discretion of the Investigator, and rituximab and lenalidomide (R2) [Arm C].
  • Have laboratory values meeting the criteria in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Had major surgery within 4 weeks prior to randomization.
  • Have active cytomegalovirus (CMV) disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,095 participants (actual)

Study arms

  • Experimental
    Arm A1: Epcoritamab + Lenalidomide and Rituximab (R2)

    Participants will receive epcoritamab in combination with R2 (ER2), followed by epcoritamab during the 120 week treatment duration.

    Drug: Epcoritamab · Drug: Rituximab · Drug: Lenalidomide

  • Experimental
    Arm A2: Epcoritamab + Lenalidomide and Rituximab (R2)

    Participants will receive epcoritamab in combination with R2 (ER2), during the 24 week treatment duration.

    Drug: Epcoritamab · Drug: Rituximab · Drug: Lenalidomide

  • Experimental
    Arm B: Chemoimmunotherapy (CIT) Option A

    Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) \[G-CHOP\]/ rituximab (R)-CHOP during the 120 week treatment duration.

    Drug: Prednisone · Drug: Rituximab · Drug: Doxorubicin · Drug: Vincristine · Drug: Cyclophosphamide · Drug: Obinutuzumab

  • Experimental
    Arm B: Chemoimmunotherapy (CIT) Option B

    Participants will receive CIT Option B (G and bendamustine (Benda) \[G-Benda\]/R-Benda during the 120 week treatment duration.

    Drug: Prednisone · Drug: Rituximab · Drug: Obinutuzumab · Drug: Bendamustine

  • Experimental
    Arm C: Lenalidomide and Rituximab (R2)

    Participants will receive lenalidomide and rituximab (R2) during the 120 week treatment duration.

    Drug: Rituximab · Drug: Lenalidomide

Interventions

06

What researchers measure

Primary outcomes

  1. Arm A1 vs Arm B: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30)

    CR30 will be determined by positron emission tomography-computerized tomography (cat scan) \[PET-CT\] per Lugano 2014 criteria, as assessed by independent review committee (IRC).

    Time frame: Up to 30 Months

  2. Arm A1 vs Arm B: Number of Participants with Progression-free survival (PFS)

    PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.

    Time frame: Up to 10 Years

Secondary outcomes

  1. Arm A1 vs Arm B: Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death of any cause.

    Time frame: Up to 10 Years

  2. Arm A1 vs Arm B: Rate of Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with follicular lymphoma (FL) MRD at baseline.

    Time frame: Up to 10 Years

  3. Arm A1 vs Arm B: Change from Baseline in Physical Functioning (PF) According to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer (EORTC QLQ-C30)

    The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

    Time frame: 21 Weeks

  4. Arm A1 vs Arm A2: Percentage of Participants who Achieve CR30

    CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 30 Months

  5. Arm A1 vs Arm C: Percentage of Participants who Achieve CR30

    CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 30 Months

  6. Arm A1 vs Arm A2: Number of Participants with PFS

    PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.

    Time frame: Up to 10 Years

  7. Arm A1 vs Arm C: Number of Participants with PFS

    PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.

    Time frame: Up to 10 Years

  8. Arm A1 vs Arm A2: Rate of MRD Negativity

    MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline.

    Time frame: Up to 10 Years

  9. Arm A1 vs Arm C: Rate of MRD Negativity

    MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline.

    Time frame: Up to 10 Years

  10. Arm A1 vs Arm A2: Change from Baseline in PF According to EORTC QLQ-C30

    The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

    Time frame: Up to 10 Years

  11. Arm A1 vs Arm C: Change from Baseline in PF According to EORTC QLQ-C30

    The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

    Time frame: Up to 10 Years

  12. Arm A1 vs Arm A2: OS

    OS is defined as the time from the date of randomization to the date of death of any cause.

    Time frame: Up to 10 Years

  13. Arm A1 vs Arm C: OS

    OS is defined as the time from the date of randomization to the date of death of any cause.

    Time frame: Up to 10 Years

  14. Arm A1 vs Arm A2: Percentage of Participants who Achieve CR30

    CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 30 Months

  15. Arm A1 vs Arm B: Percentage of Participants who Achieve CR30

    CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 30 Months

  16. Arm A1 vs Arm C: Percentage of Participants who Achieve CR30

    CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 30 Months

  17. Arm A1 vs Arm A2: Number of Participants with PFS

    PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

    Time frame: Up to 10 Years

  18. Arm A1 vs Arm B: Number of Participants with PFS

    PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

    Time frame: Up to 10 Years

  19. Arm A1 vs Arm C: Number of Participants with PFS

    PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

    Time frame: Up to 10 Years

  20. Arm A1 vs Arm A2: Percentage of Participants with Change in CR Rate per IRC

    CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  21. Arm A1 vs Arm A2: Percentage of Participants with Change in CR Rate per Investigator

    CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  22. Arm A1 vs Arm B: Percentage of Participants with Change in CR Rate per IRC

    CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  23. Arm A1 vs Arm B: Percentage of Participants with Change in CR Rate per Investigator

    CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  24. Arm A1 vs Arm C: Percentage of Participants with Change in CR Rate per IRC

    CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  25. Arm A1 vs Arm C: Percentage of Participants with Change in CR Rate per Investigator

    CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  26. Arm A1 vs Arm A2: Number of Participants with Best Overall Response (BOR) per per Investigator

    BOR is defined as the percentage of participants who achieve CR or partial response (PR) determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

    Time frame: Up to 10 Years

  27. Arm A1 vs Arm A2: Number of Participants with BOR per IRC

    BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.

    Time frame: Up to 10 Years

  28. Arm A1 vs Arm B: Number of Participants with BOR per Investigator

    BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

    Time frame: Up to 10 Years

  29. Arm A1 vs Arm B: Number of Participants with BOR per IRC

    BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.

    Time frame: Up to 10 Years

  30. Arm A1 vs Arm C: Number of Participants with BOR per Investigator

    BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

    Time frame: Up to 10 Years

  31. Arm A1 vs Arm C: Number of Participants with BOR per IRC

    BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.

    Time frame: Up to 10 Years

  32. Arm A1 vs Arm A2: Number of Participants with Event-free Survival (EFS) per IRC

    EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.

    Time frame: Up to 10 Years

  33. Arm A1 vs Arm A2: Number of Participants with EFS per Investigator

    EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

    Time frame: Up to 10 Years

  34. Arm A1 vs Arm B: Number of Participants with EFS per IRC

    EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.

    Time frame: Up to 10 Years

  35. Arm A1 vs Arm B: Number of Participants with EFS per Investigator

    EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

    Time frame: Up to 10 Years

  36. Arm A1 vs Arm C: Number of Participants with EFS per IRC

    EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.

    Time frame: Up to 10 Years

  37. Arm A1 vs Arm C: Number of Participants with EFS per Investigator

    EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.

    Time frame: Up to 10 Years

  38. Arm A1 vs Arm A2: Duration of Response (DOR) per IRC

    DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  39. Arm A1 vs Arm A2: DOR per Investigator

    DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  40. Arm A1 vs Arm B: DOR per IRC

    DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  41. Arm A1 vs Arm B: DOR per Investigator

    DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  42. Arm A1 vs Arm C: DOR per IRC

    DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  43. Arm A1 vs Arm C: DOR per Investigator

    DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  44. Arm A1 vs Arm A2: Duration of Complete Response (DOCR) per IRC

    DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  45. Arm A1 vs Arm A2: DOCR per Investigator

    DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  46. Arm A1 vs Arm B: DOCR per IRC

    DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  47. Arm A1 vs Arm B: DOCR per Investigator

    DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  48. Arm A1 vs Arm C: DOCR per IRC

    DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  49. Arm A1 vs Arm C: DOCR per Investigator

    DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  50. Arm A1 vs Arm A2: Time to Next Anti-lymphoma Therapy (TTNT) per Investigator

    TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

    Time frame: Up to 10 Years

  51. Arm A1 vs Arm A2: TTNT per IRC

    TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

    Time frame: Up to 10 Years

  52. Arm A1 vs Arm A2: TTNT per Investigator

    TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

    Time frame: Up to 10 Years

  53. Arm A1 vs Arm B: TTNT per IRC

    TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

    Time frame: Up to 10 Years

  54. Arm A1 vs Arm B: TTNT per Investigator

    TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

    Time frame: Up to 10 Years

  55. Arm A1 vs Arm C: TTNT per IRC

    TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

    Time frame: Up to 10 Years

  56. Arm A1 vs Arm C: TTNT per Investigator

    TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.

    Time frame: Up to 10 Years

  57. Arm A1 vs Arm A2: Time to Progression per IRC

    Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  58. Arm A1 vs Arm A2: Time to Progression per Investigator

    Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  59. Arm A1 vs Arm B: Time to Progression per IRC

    Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  60. Arm A1 vs Arm B: Time to Progression per Investigator

    Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  61. Arm A1 vs Arm C: Time to Progression per IRC

    Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.

    Time frame: Up to 10 Years

  62. Arm A1 vs Arm C: Time to Progression per Investigator

    Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.

    Time frame: Up to 10 Years

  63. Arm A1 vs Arm A2: Number of Participants with Progression-free Survival After Subsequent Anti-Lymphoma Therapy (PFS2)

    PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

    Time frame: Up to 10 Years

  64. Arm A1 vs Arm B: Number of Participants with PFS2

    PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

    Time frame: Up to 10 Years

  65. Arm A1 vs Arm C: Number of Participants with PFS2

    PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.

    Time frame: Up to 10 Years

  66. Arm A1 vs Arm A2: Change in Tolerability as Measured by Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.

    Time frame: Up to 10 Years

  67. Arm A1 vs Arm B: Change in Tolerability as Measured by PRO-CTCAE

    The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.

    Time frame: Up to 10 Years

  68. Arm A1 vs Arm C: Change in Tolerability as Measured by PRO-CTCAE

    The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.

    Time frame: Up to 10 Years

  69. Arm A1 vs Arm A2: Change in Tolerability as Measured by The Functional Assessment of Cancer Therapy - General (FACT-G) Item GP5

    The functional assessment of cancer therapy singly item - GP5 (FACT-GP5) is a single question asking if participant is bothered by side effects of treatment.

    Time frame: Up to 10 Years

  70. Arm A1 vs Arm B: Change in Tolerability as Measured by FACT-G Item GP5

    The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment.

    Time frame: Up to 10 Years

  71. Arm A1 vs Arm C: Change in Tolerability as Measured by FACT-GG Item GP5

    The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment.

    Time frame: Up to 10 Years

  72. Arm A1 vs Arm A2: Change in Symptoms as Measured by The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)

    The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

    Time frame: Up to 10 Years

  73. Arm A1 vs Arm B: Change in Symptoms as Measured by FACT-Lym

    The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

    Time frame: Up to 10 Years

  74. Arm A1 vs Arm C: Change in Symptoms as Measured by FACT-Lym

    The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

    Time frame: Up to 10 Years

  75. Arm A1 vs Arm A2: Change in Quality of Life (QoL) as Measured by FACT-Lym

    The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

    Time frame: Up to 10 Years

  76. Arm A1 vs Arm B: Change in QoL as Measured by FACT-Lym

    The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

    Time frame: Up to 10 Years

  77. Arm A1 vs Arm C: Change in QoL as Measured by FACT-Lym

    The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

    Time frame: Up to 10 Years

  78. Arm A1 vs Arm A2: Time-to-first PRO deterioration (TTD) in well-being using the lymphoma subscale (LymS) of FACT-Lym

    The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

    Time frame: Up to 10 Years

  79. Arm A1 vs Arm B: TTD in well-being using LymS of FACT-Lym

    The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

    Time frame: Up to 10 Years

  80. Arm A1 vs Arm C: TTD in well-being using LymS of FACT-Lym

    The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.

    Time frame: Up to 10 Years

  81. Arm A1 vs Arm A2: Change in QoL as Measured by 5-Level European Quality of Life (EuroQol)-5-dimension [EQ-5D-5L]

    The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.

    Time frame: Up to 10 Years

  82. Arm A1 vs Arm B: Change in QoL as Measured by EQ-5D-5L

    The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.

    Time frame: Up to 10 Years

  83. Arm A1 vs Arm C: Change in QoL as Measured by EQ-5D-5L

    The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.

    Time frame: Up to 10 Years

  84. Arm A1 vs Arm A2: TTD in PF using the QLQ-C30 Physical Functioning Scale

    The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

    Time frame: Up to 10 Years

  85. Arm A1 vs Arm B: TTD in PF using the QLQ-C30 Physical Functioning Scale

    The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

    Time frame: Up to 10 Years

  86. Arm A1 vs Arm C: TTD in PF using the QLQ-C30 Physical Functioning Scale

    The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.

    Time frame: Up to 10 Years

  87. Arm A1 vs Arm A2: Change from baseline in the remaining items and domains of the EORTC QLQ-C30

    The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.

    Time frame: Up to 10 Years

  88. Arm A1 vs Arm B: Change from baseline in the remaining items and domains of the EORTC QLQ-C30

    The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.

    Time frame: Up to 10 Years

  89. Arm A1 vs Arm C: Change from baseline in the remaining items and domains of the EORTC QLQ-C30

    The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.

    Time frame: Up to 10 Years

  90. Arm A1 vs Arm A2: Change in Patient Global Impression of Change (PGIC) for General Lymphoma Symptoms

    The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.

    Time frame: Up to 10 Years

  91. Arm A1 vs Arm C: Change in PGIC for General Lymphoma Symptoms

    The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.

    Time frame: Up to 10 Years

  92. Arm A1 vs Arm A2: Change in Patient Global Impression of Severity (PGIS) for General Lymphoma Symptoms

    The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.

    Time frame: Up to 10 Years

  93. Arm A1 vs Arm B: Change in PGIS for General Lymphoma Symptoms

    The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.

    Time frame: Up to 10 Years

  94. Arm A1 vs Arm C: Change in PGIS for General Lymphoma Symptoms

    The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.

    Time frame: Up to 10 Years

07

Study locations

266 sites

Showing the first 100 of 266 sites across 32 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Nov 2037, 165 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's planned 165 months is above that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Jan 5, 2024
StartActual
Feb 5, 2024
Primary completionEst.
Nov 2037
CompletionEst.
Nov 2037
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06191744
Lead sponsor
Genmab
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Feb 5, 2024
Primary completion
Nov 2037 (estimated)
Completion
Nov 2037 (estimated)
Last update
Aug 4, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Epcoritamab · Lenalidomide

Start the discussion